The nasal vaccine, tested on animals since 2021, may offer a new tool in fighting COVID-19 with a non-invasive, ...

New targeted delivery technology offers hope for aggressive brain cancer treatment.

This came after the firm presented their proposal for the manufacturing and marketing of Roflumilast Cream 0.3% w/w for the ...

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025Glasgow, Scotland - 28 April 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a Live streamed of quarterly presentation in English ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world ...

Uganda has officially declared the end of its recent Ebola outbreak, following a rapid and coordinated response that involved ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...